Clinical trials
Cardiomyopathy, Hypertrophic trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 8 |
| 2024 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 22 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Xijing Hospital | 6 |
| China National Center for Cardiovascular Diseases | 3 |
| Beijing Institute of Heart, Lung and Blood Vessel Diseases | 2 |
| Hangzhou Valgen Medtech Co., Ltd | 2 |
| Xiang Wei | 2 |
| First Hospital of China Medical University | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Qilu Hospital of Shandong University | 1 |
| Second Xiangya Hospital of Central South University | 1 |
| Shanghai Zhongshan Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cardiomyopathy, Hypertrophic | 22 |
| Arrhythmogenic Right Ventricular Dysplasia | 2 |
| Cardiomyopathy, Dilated | 2 |
| Cardiomyopathy, Restrictive | 2 |
| Fabry Disease | 2 |
| Hypertrophy, Left Ventricular | 2 |
| Postoperative Complications | 2 |
| Amyloid Neuropathies, Familial | 1 |
| Arrhythmias, Cardiac | 1 |
| Cardiomyopathies | 1 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.